

Oral Potentially Malignant Disorders Day (OPMDDay)

University of Zagreb, School of Dental Medicine –
Zagreb – Croatia, June 12–13th

DAY 1 – 12 th of June 2025 – INTERCEPTOR Day		
	Topic	Who
09:00-09:45	Registration and check-in	
09:45-10:00	Welcome & objectives of the day	
10:00-12:00	Working Group plenary session - Summarize past initiatives (30min) - Discuss the next steps and activities (STSMs, TS, Dissemination grants...)	Sequentially: - WGs 1, 2, 3 and 6 (15') - WGs 4,5 (15') - WG7 (15')
12:00-13:30	<i>**lunch break**</i>	
13:30-17:30	Parallele sessions	
13:30-14:30	POSTER SESSION	
14:30-16:00		<i>OPMDDBoard</i>
16:00-17:30		Management Committee / Core Group meeting
19:30	<i>**Dinner**</i>	

DAY 2 – 13th of June 2025 – OPMDay		
	Topic	Who
08:00-08:30	Venue and Registration	
08:30-09:00	Welcome: OPMD in Croatia (Presented by Danica Vidović Juras and Petar Ozretić + Chair and Co-chair	
09:00-10:30	Biomarkers and biological mechanisms	
09:00-09:30	Keynote 1: Title to be confirmed	Silvio Gutkind (USA)
09:30-09:50	Pre-clinical review on OPMDs	Izge Shanliturk (Cyprus)
09:50-10:10	Genetic evolution of normal looking mucosa	Pierre Martinez (France)
10:10-10:30	TBC	
10:30-11:15	<i>**coffee break and poster view**</i>	
11:15-12:30	Patient voices	
12:30 - 14:00	<i>**lunch break**</i>	
14:00-15:30	Clinical and Pathological Diagnosis (Moderators : Mark Lingen/ Keith Hunter)	
14:00-14:30	Keynote 2: AI and dysplasia	Ali Khurram/Hanya Mahmood (UK)
14:30-14:50	Defining essential criteria for the diagnosis of OED	Senada Koljenovic (BE)/ Ali Khurram (UK)
14:50-15:10	E-health systematic review from WG3	Anneze Odendaal (ZA)/ Gennaro Musella (IT)
15:10-15:30	Clinical review (prevention, diagnosis, prognosis and treatment)	Bojan Poposki (MK)
15:30-15:50	Progression to malignancy in oral potentially malignant disorders: a retrospective study of 5,036 patients in Ontario, Canada	Mark Darling (CA)
15:50-16:15	<i>**coffee break**</i>	
16:15-17:45	Disease care management	
16:15-16:45	Overview on clinical care and Fanconi tumor board	Eunike Velleuer (DE)
16:45-17:05	Clinical PI on a French clinical trial named FANCORAL	Arnaud Beddok (FR)
17:05-17:25	What is the role of immunotherapy in the management of OPMD?	Luigi Lorini (IT)
17:25-17:45	SAVER TRIAL	Caroline McCarty (UK)
17:45-18:00	TBC	
18:00-18:15	Wrap-up and closing remarks	

Scientific Board

Rui Amaral Mendes	<p>Professor, Faculty of Medicine, University of Porto - MEDCIDS - Department of Community Medicine, Information and Health Decision Sciences</p> <p>Researcher at CINTESIS@RISE, Faculty of Medicine, University of Porto (Clinical and Translational Research in Oncology) Adjunct Professor of Oral and Maxillofacial Medicine, Department of Oral and Maxillofacial Medicine and Diagnostic. Sciences, Case Western Reserve University, Cleveland, OH, USA</p>
Paolo Bossi	Professor at Humanitas University and Humanitas Cancer center, Italy
Marine Benaïssa	Science Communication Coordinator & INTERCEPTOR Project Manager, Department of Translational Medicine, Centre Léon Bérard, Lyon 69008, France
Antonella Cardone	CEO of Cancer Patients Europe, the pan-European and all-cancer types patient association, Belgium
Daniela Elena Costea	<p>Professor, Gade Laboratory for Pathology, Department of Clinical Medicine and Centre for Cancer Biomarkers CCBio,</p> <p>Haukeland University Hospital, University of Bergen, Norway</p>
Susanna Chiocca	Director, Viruses and Cancer Unit, Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Moshe Elkabets	Associate Professor at Ben-Gurion University. Research focus on development & therapy of head and neck cancer. Drug resistance, tumor microenvironment and immunity, Israel.
Haly Holmes	Periodontist at University of the Western Cape. University of the Western Cape. City of Cape Town, Western Cape, South Africa
Keith Hunter	<p>Professor of Head and Neck Pathology, Liverpool Head and Neck Centre, Molecular and Clinical Cancer Medicine, University</p> <p>of Liverpool, United-Kingdom</p>
Senada Koljenović	Professor and Head of Department of Pathology, Antwerp University Hospital/ University of Antwerp, Belgium
Zisis Kozlakidis	Head of the Laboratory Services and Biobank Group (LSB) at IARC, WHO.
Petar Ozretić	Senior Research Associate at Ruđer Bošković Institute, Head of Laboratory for Hereditary Cancer, Zagreb, Croatia. Adjunct Assistant Professor at Josip Juraj Strossmayer University of Osijek, Osijek, Croatia.
Carina Ladeira	Professor, Higher School of Health Technologies of Lisbon – Polytechnic University of Lisbon. Department of Diagnosis Sciences, Therapeutics and

	Public Health. Researcher in H&TRC- Health & Technology Research Center and NOVA - National School Public Health Research Centre.
Valesca Retèl	Head Health Technology Assessment (HTA) department, Netherlands Cancer Institute, Professor translational HTA - Erasmus University Rotterdam, The Netherlands
Pierre Saintigny	Department of Medical Oncology, Centre Léon Bérard, Lyon, France ; Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon 69008, France.
Dipak Sapkota	Professor, Department of Oral Biology, Faculty of Dentistry, University of Oslo, Norway - Academic editor of The Norwegian Dental Journal
Merva Soluk Tekkeşin	Grant Awarding Coordinator of the COST Action INTERCEPTOR and Professor of Oral Pathology - Department of Tumour Pathology - Institute of Oncology, Istanbul University - 34093 Capa- Istanbul, Turkey
Danica Vidović Juras	Oral medicine specialist, Head of the Department of Oral Medicine at School of Dental Medicine University of Zagreb and Head of the Department of Oral Diseases